Artificial intelligence company SandboxAQ has just announced a partnership with Anthropic to integrate scientific research and drug discovery tools onto the Claude platform.
This agreement is expected to help scientists and pharmaceutical businesses access in-depth AI technology more easily through natural language instead of having to use complex programming systems.
According to SandboxAQ, Claude users can now ask questions or request research in the common language to access AI models for drug discovery. This significantly reduces the technical barriers that have long existed in the field of AI-based pharmaceutical research.
Drug discovery is one of the most expensive and long-lasting fields in modern science. The process of finding a molecule that has the potential to become a new drug often takes many years of research and costs up to billions of USD.
Although many AI companies have developed tools to accelerate this process, most still require programming expertise or specialized computing systems.
SandboxAQ believes that integration with Claude will help researchers access scientific AI technology more easily without needing too much technical knowledge.
SandboxAQ is currently chaired by former Google CEO Eric Schmidt and operates in many fields such as quantitative research, science AI and cybersecurity.
One of the core technologies of SandboxAQ is Large Quantitative Models (LQM).
Unlike traditional AI models that mainly learn from text data, LQM is built on physical equations and practical scientific laws.
According to the company, this approach allows the system to predict the behavior of molecules even before conducting experiments in the laboratory.
This approach can help scientists identify potential molecules early before putting them into actual testing, thereby shortening research time and reducing costs for ineffective tests.
Nadia Harhen, General Director of AI simulation at SandboxAQ, said this is the first time an advanced scientific quantitative model has been combined with a modern conversational AI platform, allowing users to access it in natural language.
According to Harhen, SandboxAQ's customers are often research scientists, computational science groups and pharmaceutical companies looking for new materials or drug candidates. Ms. Harhen also said that many businesses come to SandboxAQ after encountering difficulties in turning calculation results into practical scientific applications.
SandboxAQ said the company is operating in a field called the quantitative economy, where AI and computing models are applied to industries that need complex data analysis and simulation such as pharmaceuticals, finance, energy and new material research.
The company believes that combining conversational AI with complex scientific models will help expand access to this technology beyond the scope of technical experts.
